Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.50 USD
Change Today +0.97 / 3.18%
Volume 2.0M
DEPO On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

James A. Schoeneck

Chief Executive Officer, President and Director, DepoMed Inc.
AgeTotal Calculated CompensationThis person is connected to 16 board members in 2 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. James A. Schoeneck, also known as Jim has been the Chief Executive Officer and President of DepoMed Inc., since April 18, 2014. Mr. Schoeneck serves as a Strategic Advisor to Kreido Laboratories. He served as the Chief Executive Officer of BrainCells Inc. since October 2005. Mr. Schoeneck served as Chief Executive Officer of ActivX Biosciences Inc., from November 2003 to December 2004. Mr. Schoeneck served as President and Chief Executive Officer of Prometheus Laboratories ...

Read Full Background

Corporate Headquarters*

7999 Gateway Boulevard
Newark, California 94560

United States

Phone: 510-744-8000
Fax: 510-744-8001

Board Members Memberships*

Chief Executive Officer, President and Director
Non-Employee Director, Chairman of Compensation Committee and Member of Audit Committee


Jacksonville State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$620,058

Stock Options*

Restricted Stock Awards$1,548,180
All Other Compensation$14,320
Exercised Options100,700
Exercised Options Value$642,766
Exercisable Options644,862
Exercisable Options Value$5,113,512
Unexercisable Options411,438
Unexercisable Options Value$2,413,853
Total Value of Options$8,170,131
Total Number of Options1,157,000

Total Compensation*

Total Annual Cash Compensation$1,159,378
Total Short Term Compensation$620,058
Other Long Term Compensation$1,562,500
Total Calculated Compensation$4,068,452
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $31.50 USD +0.97


Ron Cohen M.D.Founder, Chief Executive Officer, President and Director
Acorda Therapeutics, Inc.
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
Jack A. Khattar Founder, Chief Executive Officer, President, Secretary and Director
Supernus Pharmaceuticals, Inc.
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
Michael L. Babich Chief Executive Officer, President and Director
INSYS Therapeutics, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at